PharmaCielo is a cannabis stock to watch this summer, GMP says
Cannabis extract company PharmaCielo (PharmaCielo Stock Quote, Chart TSXV:PCLO) is ramping up production, which is good news for the stock going forward, says GMP Securities analyst Robert Fagan.
On Tuesday, Fagan reacted to the company’s latest quarterly earnings by maintaining his “Buy” rating and $12.00 target price.
PharmaCielo, which is based in Toronto and has PharmaCielo Columbia Holdings as its principal and wholly owned subsidiary, released its first quarter fiscal 2019 results on Monday.
In the company’s quarterly press release, CEO David Attard said it has made significant progress over the past six months towards generating commercial sales by the second half of 2019. … Read more.